Issue link: https://www.e-digitaleditions.com/i/1417310
This section provides information that may be useful in research and development or manufacturing. Content is provided by the companies listed. No endorsement or preference is intended. 18 OctOber 2021 Inhalation Issue Focus This section of Inhalation provides information that may be useful in research and development or manufacturing. Content is provided by the companies listed. No product endorsement or preference is intended. devices Automated device testing When testing a wide range of inhaled devices, greatly reduce analyst time and generate results faster with Astech's Xelox ® automated NGI Particle Size Determination (PSD) solutions. Astech provides semi-automated and fully automated PSD testing systems, using the latest technology, which enable traceable test data at each step. Our Relovex ® software enables user friendly, 21 CFR Part 11 compliant data capture, storage and retrieval. A testing system can be installed as a standalone unit or integrated into Astech's full range of automated testing systems. Astech Projects UK: +44 1928 571797 www.astechprojects.co.uk Automated nasal spray dose collection and wasting New for 2021, the Nasal Spray Dose Collector (NSDC) and Nasal Spray Waste Collector (NSWC) used together with the Vertus II/Plus automate the delivered dose uniformity testing and wasting of nasal sprays. e NSDC and NSWC have been specially designed to help reduce costly out-of- specification results and boost productivity. Learn more at bit.ly/ NSDC_NSWC. Copley Scientific UK: +44 1159 616229 www.copleyscientific.com Early preclinical research services Inhalation Sciences offers early preclinical research ser- vices with its Inhalation Research Services (IRS). In addition, its PreciseInhale ® platform enables precision dosing with minimal substance consumption (< 100 mg), for a complete PK study. Using the same aerosol dispensing system, translational errors are minimized when comparing data from in vitro dissolution and absorption, in vivo nose-only or intratracheal expo- sures, and ex vivo isolated perfused lung (IPL). Identify the most promising drug candidates early, while sav- ing costs, animals and development time. Inhalation Sciences Sweden: +46 705 625 195 www.inhalation.se